Yatharth Hospital gets CCI approval for 24.87% investment

Yatharth Hospital & Trauma Care Services Limited said the Competition Commission of India cleared on November 10, 2026 Rasmalai Limited’s proposed Rs 3,150 crore preferential issue, which would leave the Cyprus-incorporated investor with 24.87% of the company’s post-issue fully diluted share capital, subject to other regulatory and statutory requirements.

What did the CCI approve for Yatharth Hospital?

The Competition Commission of India (CCI) approved Rasmalai’s proposed combination involving Yatharth Hospital under Section 31(1) of the Competition Act, 2002, at its November 10, 2026 meeting. Yatharth Hospital disclosed receipt of the CCI approval in its November 12, 2026 filing to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The approval concerns a proposed preferential issue by private placement to Rasmalai, rather than an identified purchase of existing shares from current shareholders. The company described Rasmalai as a company incorporated under the laws of Cyprus and identified it as the investor for the proposed issuance and allotment of securities. The CCI communication records the matter as Combination Registration No. C-2026/09/1477.

The CCI letter said the Commission considered and approved the proposed combination under Section 31(1), but said its order would follow. As a result, the November 10 communication does not set out the competition assessment, any detailed reasoning, remedies or conditions that may be contained in the subsequent order. Yatharth Hospital’s November 12 disclosure similarly reports the approval without providing those details.

How large is Rasmalai’s proposed investment in Yatharth Hospital?

Rasmalai is proposed to provide aggregate cash consideration of approximately Rs 3,150 crore through the preferential issue, and the securities would represent 24.87% of Yatharth Hospital’s post-issue share capital on a fully diluted basis. Yatharth Hospital called the proposed holding a minority investment in its November 12, 2026 announcement.

The 24.87% figure is specifically calculated after the proposed issue and on a fully diluted basis, rather than as a percentage of Yatharth Hospital’s existing share capital. The filing does not disclose the number of securities, their class, their issue price or the dates on which they would be issued and allotted. It therefore establishes the proposed consideration and ownership percentage, but not the instrument-level terms of the issue.

The proposed Rs 3,150 crore consideration is attached to a fresh preferential issue by Yatharth Hospital, based on the company’s description of an issuance and allotment on a private-placement basis. This differs from a filing that would describe a secondary share transfer, because the disclosed route is an issue of securities by the company to Rasmalai. The announcement does not state how the cash consideration would be used after receipt.

When did the Yatharth Hospital transaction move through CCI review?

Rasmalai filed the CCI notice on September 29, 2026, and the Commission approved the proposed combination at its November 10, 2026 meeting. Yatharth Hospital then informed the stock exchanges on November 12, 2026 that it had received the approval letter dated November 10. The disclosed sequence spans a September 29 competition filing, a November 10 approval and a November 12 market announcement.

Yatharth Hospital also referred to an earlier company letter dated September 22, 2026 concerning the preferential issue. That September 22 company notice preceded Rasmalai’s September 29 notice to the CCI by seven calendar days. The documents do not disclose whether any action occurred between the September 22 company notice and the September 29 combination filing beyond the filing itself.

The CCI communication identifies the filing as one made under Section 6(2) of the Competition Act, 2002 and under the Competition Commission of India (Combinations) Regulations, 2024. It says the Commission considered the transaction at the November 10 meeting before approving it under Section 31(1). The letter does not provide a separate closing timetable for the Rs 3,150 crore preferential issue.

Does CCI approval complete Rasmalai’s investment in Yatharth Hospital?

No, the November 10 CCI approval does not complete Rasmalai’s proposed investment because Yatharth Hospital said the transaction remains subject to fulfilment of other applicable regulatory and statutory requirements. The November 12 filing does not identify those outstanding requirements or say that the proposed securities have been issued, allotted or paid for.

This distinction means the announced 24.87% holding remains a proposed post-issue outcome in the supplied disclosure. Yatharth Hospital used future-oriented wording for the securities that “shall represent” the minority investment after issuance and allotment. Neither the company announcement nor the CCI letter reports that Rasmalai has become a shareholder as of November 12, 2026.

The CCI decision resolves the competition-law review described in Combination Registration No. C-2026/09/1477, but it is only one disclosed step in the transaction process. Yatharth Hospital did not state whether shareholder approval, additional regulator approvals, stock-exchange procedures or other statutory actions were among the pending conditions. It also did not provide an expected completion date for the preferential issue.

What does the CCI decision disclose about the transaction terms?

The CCI decision discloses approval of the proposed combination, but not the detailed terms or assessment that will appear in the Commission’s forthcoming order. The November 10 letter expressly says the order will follow, while Yatharth Hospital’s November 12 announcement provides the proposed Rs 3,150 crore cash consideration and 24.87% fully diluted ownership outcome.

The available documents do not state whether the CCI imposed conditions on the transaction, because the communication only records approval under Section 31(1). They also do not disclose a valuation, a per-security subscription price, governance rights, board representation, lock-in terms or any operating commitments by Rasmalai. Those matters cannot be inferred from a 24.87% post-issue holding alone.

Yatharth Hospital’s filing does provide a clear regulatory boundary: the CCI considered the transaction as a combination after Rasmalai’s September 29, 2026 notice. Yet the company’s notice also preserves the need for other applicable regulatory and statutory requirements. The next formal CCI document, when issued, is the disclosed source expected to provide the Commission’s order on Combination Registration No. C-2026/09/1477.

Conclusion

The November 10, 2026 CCI approval advances Rasmalai’s proposed Rs 3,150 crore investment in Yatharth Hospital through a private-placement preferential issue. If issued and allotted as described, the securities would give Rasmalai 24.87% of Yatharth Hospital’s post-issue fully diluted share capital, which the company has characterised as a minority investment.

The next matters to watch are the other regulatory and statutory requirements that Yatharth Hospital says remain outstanding, along with any disclosure of the issue terms, allotment and completion date. The CCI also said its order would follow, leaving its detailed analysis and any transaction conditions undisclosed in the November 10 communication.